• 早期公開 J-Stage
• 地方会後抄録の検索方法について
• 転載許諾に関する規程

Vol.64

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.63

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.62

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.61

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.60

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.59

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.58

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.57

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.56

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.55

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.54

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.53

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.52

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.51

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.50

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.49

• No.1
• No.2/3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.48

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

• Vol.47から1まではこちら
  会員専用

• ホーム
• 47巻11号
• 臨床神経, 47：835−837, 2007
• 47巻11号目次

第48回日本神経学会総会

＜シンポジウム2-5＞神経伝達機能イメージング：Cutting Edge
アデノシン受容体―ドパミンとの関連―

三品　雅洋^1）2）, 石井　賢二^2）, 石渡　喜一^2）

^1）日本医科大学千葉北総病院脳神経センター〔〒270-1694　千葉県印旛郡印旛村鎌苅1715〕
^2）東京都老人総合研究所ポジトロン医学研究施設

Adenosine is produced by conversion of intra- and extracellular adenine nucleotides, and plays a role as an endogenous modulator of synaptic functions in the central nervous system. The adenosine A_2A receptors (A_2AR) are enriched in dopamine-rich areas of the brain, such as the basal ganglia, and are thought to interact with dopamine D₂ receptor (D₂R) negatively. Selective A_2AR antagonists have attracted attention as the treatment of Parkinson's disease (PD). Little information was available about the receptor in the living human brain until quite recently. However, we developed a PET ligand, [7-methyl-¹¹C]-(E)-8- (3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine ([¹¹C]TMSX), for mapping the A_2AR. We reported that the binding potential (BP) of[¹¹C]TMSX in normal human brain was the largest in the putamen, and was small in the cerebral cortex. Next, we investigated the relationship between A_2AR in the drug naive PD. We found that the BP of[¹¹C]TMSX was significantly lower on the more affected side than the less affected side of the putamen in PD patients. Release of dopamine is reduced asymmetrically in the putamen of early PD, and D₂R are up-regulated as compensation for the decrease of dopamine. Our data showed that reaction of the A_2AR was opposite to the D₂R.

(臨床神経, 47：835−837, 2007)
key words：アデノシンA_2A受容体, ポジトロンCT, アデノシンA₁受容体, ドパミン, パーキンソン病

（受付日：2007年5月16日）